Narcolepsy is not associated with increased risk for mortality of any type, even among patients with a higher prevalence of psychiatric comorbidities, new research shows.
VTRS acquires Aculys Pharma to boost its CNS portfolio in Japan, gaining rights to pitolisant and Spydia for narcolepsy and ...
Strengthens Viatris' Presence in Japan With the Addition of Two Innovative Assets Targeting Areas of Significant Unmet Medical Need Leverages Existing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback